Evidence map›Paper›PMID 12435805›Full record

ArticleMolecular pharmacology2002

A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.

M L Trincavelli, D Tuscano, M Marroni, A Falleni, V Gremigni, S Ceruti, M P Abbracchio, K A Jacobson, F Cattabeni, C Martini

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 73 citations in OpenAlex.

  1. Covalently Binding Adenosine APurinergic signalling · 2024
    Article
  2. Species dependence of APurinergic signalling · 2023
    Review
  3. Activation of Adenosine AInternational journal of molecular sciences · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. AMedicinal research reviews · 2018
    Review
  8. Article
  9. Article
  10. PreclinicalContrast media & molecular imaging · 2018
    Article
  11. Ocular Purine Receptors as Drug Targets in the Eye.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2016
    Review
  12. Review
  13. Article
  14. Adenosine receptors: expression, function and regulation.International journal of molecular sciences · 2014
    Review
  15. Purinergic signalling and cancer.Purinergic signalling · 2013
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

M L TrincavelliDipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, Universitá Pisa, Pisa, Italy.
D Tuscano
M Marroni
A Falleni
V Gremigni
S Ceruti
M P Abbracchio
K A Jacobson
F Cattabeni
C Martini
National Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Pisa · ITNational Institutes of Health · USUniversity of Milan · IT

Funding

Drugs that Act at Adenosine ReceptorsZ01DK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$854k
Intramural NIH HHS Z01 DK031117Intramural NIH HHS Z99 DK999999
6 · The paper itself

Abstract

A(3) adenosine receptor activation has been previously demonstrated to result in both neuroprotective and neurodegenerative effects, depending upon specific pathophysiological conditions. This dual effect may depend on receptor regulation mechanisms that are able to change receptor availability and/or function. In the present study, we investigated desensitization, internalization, and down-regulation of native A(3) adenosine receptors in human astrocytoma cells after exposure to the agonist 2-chloro-N6-(3-iodobenzyl)-N-methyl-5'-carbamoyladenosine (Cl-IBMECA). Cl-IBMECA induced a concentration-dependent inhibition of adenylyl cyclase activity with an EC(50) value of 2.9 +/- 0.1 nM. The effect was suggested to be mediated by A(3) adenosine receptor subtype by the use of selective adenosine receptor antagonists. Cell treatment with pertussis toxin abolished Cl-IBMECA-mediated inhibition of adenylyl cyclase activity, evidencing an A(3) receptor coupling to inhibitory G protein. Short-term exposure to the agonist Cl-IBMECA (100 nM) caused rapid receptor desensitization, within 15 min. Agonist-induced desensitization was accompanied by receptor internalization: A(3) adenosine receptor internalized with rapid kinetics, within 30 min, after cell exposure to 100 nM Cl-IBMECA. The localization of A(3) adenosine receptors on the plasma membrane and in intracellular compartments was directly revealed by immunogold electron microscopy. After desensitization, the removal of agonist led to the restoration of A(3) adenosine receptor functioning through receptor recycling to the cell surface within 120 min. Prolonged agonist exposure (1-24 h) resulted in a marked down-regulation of A(3) adenosine receptors that reached 21.9 +/- 2.88% of control value after 24 h. After down-regulation, the recovery of receptor functioning was slow (24 h) and associated with the restoration of receptor levels close to control values. In conclusion, our results demonstrated that A(3) receptors, in astrocytoma cells, are regulated after short- and long-term agonist exposure.

Indexed as

Adenylyl CyclasesAstrocytomaDown-RegulationEndocytosisHumansPurinergic P1 Receptor AgonistsReceptor, Adenosine A3Receptors, Purinergic P1Tumor Cells, CulturedAdenylyl CyclasesPurinergic P1 Receptor AgonistsReceptor, Adenosine A3Receptors, Purinergic P1

Identifiers

PMID12435805
PMCPMC4806643
OpenAlexW2100640564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.